Fundraising Fox

Diamond Therapeutics

Toronto, CA · 2 known investors

Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds. It brings together clinical researchers and pharmaceutical development experts to advance early-stage candidates for mood and related disorders.

BiotechHealthtechMental Health

Founders & leadership

JB
Judy BlumstockChief Executive Officer, Founder, Director
MB
Michael B. McDonnellChief Medical Officer
GM
Grant McCutcheonChief Financial Officer

Investors · 2

JLSNew York
NoeticToronto

In the news

Diamond Therapeutics Receives Multi-Million Dollar US Government Funding for Phase 2 Clinical Trial of Anxiety Treatment — OBIOobio.ca · May 2026Black Diamond Therapeutics (NASDAQ:BDTX) Is In A Good Position To Deliver On Growth Plansfinance.yahoo.com · May 2026Ontario Brain Institute Increases Investment in Diamond Therapeutics to Accelerate Innovation in Mental Health - BioSpacebiospace.com · Jan 2021Black Diamond Therapeutics Raises $85M in Series C Financing - FinSMEsfinsmes.com · Dec 2019Versant’s Black Diamond raises $85M, plots transatlantic move | Fierce Biotechfiercebiotech.com · Jan 2019

Frequently asked questions

What does Diamond Therapeutics do?
Diamond Therapeutics is a preclinical biotechnology company developing drug treatments for psychiatric and neurological disorders, with a focus on the pharmacology and therapeutic use of psychedelic compounds. It brings together clinical researchers and pharmaceutical development experts to advance early-stage candidates for mood and related disorders.
Who founded Diamond Therapeutics?
Diamond Therapeutics was founded by Judy Blumstock.
Who are Diamond Therapeutics's investors?
Diamond Therapeutics's investors include JLS, Noetic.
Where is Diamond Therapeutics headquartered?
Diamond Therapeutics is headquartered in Toronto, CA.